Patient acceptability and practical implications of pharmacokinetic studies in patients with advanced cancer.
We have studied the practical implications and acceptability to patients of pharmacokinetic studies in 34 women receiving anthracyclines for advanced breast cancer. The following parameters were recorded: age, ECOG performance status, psychological state (Rotterdam Symptom Checklist), cytotoxic drug and dose, number of venepunctures for treatment and sampling, and time when the sampling cannula was removed. Immediately after finishing pharmacokinetic sampling, patients completed a questionnaire which revealed that (i) all patients understood sampling was for research, (ii) 35% of patients experienced problems with sampling, (iii) benefits from participation were perceived by 56% of patients. Of 20 patients later questioned after completion of their treatment course, 40% recalled difficulties with blood sampling. Factors identifying in advance those patients who tolerate pharmacokinetic studies poorly were not identified but the number of venepunctures should be minimised. Patients may also perceive benefits from 'non-therapeutic' research.
N A
NA
Dobbs
C J
CJ
Twelves
A J
AJ
Ramirez
K E
KE
Towlson
W M
WM
Gregory
M A
MA
Richards
D000328:Adult; D000368:Aged; D001815:Bloodletting; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy / Q000378:metabolism* / Q000523:psychology; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008875:Middle Aged; D010342:Patient Acceptance of Health Care; D011788:Quality of Life
C053044:4'-deoxy-4'-iododoxorubicin; D004317:Doxorubicin